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ABSTRACT
Current studies show  that especially pancreatic, liver, endometrial, colorectal, bladder and breast cancer incidences are increased 
by the presence of type 2 diabetes mellitus (T2DM). Possible links between T2DM and cancer include hyperinsulinemia, dysregulation 
of adipocytokines and  hyperglycemia as well as shared confounding risk factors. There is evidence emerging from experimental and 
clinical studies that metformin can play a crucial anti-cancereous role. Since 2005, multiple studies showed the association between 
metformin and the reduction of risk in cancers of pancreas, colorectal, stomach, liver, breast and esophagus in diabetes cases. It 
was also claimed to improve survival in some cancers. Metformin is an insulin sensitizer and mainly acts through inhibiting hepatic 
gluconeogenesis by activating  LKB1/AMP-activated protein kinase (AMPK). Metformin was found to have anti-cancerous and anti-
metastatic effects mainly through activating AMPK dependent and independent signaling; inhibiting mTOR, MAPK, HER2, NF-κB, IGF 
signaling pathways and with its possible immuno-modulatory effects. Further studies are needed to evaluate the potential of metformin 
as adjuvant therapy for cancer especially in non-diabetic patients.
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ÖZET
Metforminin Kanserdeki Muhtemel Rolü: Aldatmaca mı Yoksa Gerçek bir Umut mu?
Son dönemde yapılan çalışmalar, tip 2 diabetes mellitus (T2DM) varlığında özelllikle pankreas, karaciğer, endometrium, kolorektal, 
mesane ve meme kanseri insidanslarının arttığını göstermektedir. T2DM ve kanser arasındaki muhtemel bağlantılar; hiperinsülinemi, 
adipositokinlerin regülasyonunda sorunlar ve hiperglisemi ile birlikte paylaşılan karıştırıcı risk faktörlerini kapsamaktadır. Deneysel ve 
klinik çalışmalar metforminin çok önemli anti-kanseröz etkileri olduğunu ispatlamaktadır. 2005’den itibaren yapılan çok sayıda çalışma, 
diyabetik olgularda metformin ile pankreas, kolorektal, mide, karaciğer, meme ve ösefagus kanser riskinde azalma  arasında ilişkiyi 
göstermiştir. Bazı kanserlerde sürviyi arttırdığı da iddia edilmektedir. Metformin, başlıca etkisini  LKB1/AMP-activated protein kinase 
(AMPK) aktivasyonu aracılığı ile hepatik glukoneogenezi inhibe ederek insülin duyarlılığını arttıran bir ilaçtır. Metforminin, AMPK bağımlı 
ve bağımsız sinyaller aracılığı ile mTOR, MAPK, HER2, NF-κB, IGF sinyal yolaklarını inhibe ederek ve muhtemel immün-modülatuvar 
etkileri ile anti-kanseröz ve anti-metastatik etkiler gösterdiği saptanmıştır. Adjuvan kanser tedavisinde, özellikle diyabetik olmayan 
hastalarda metforminin etkilerini değerlendirmek için daha fazla çalışmaya gereksinim vardır.
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TYPE 2 DIABETES MELLITUS and CANCER
Type 2 diabetes mellitus (T2DM) was studied in 
relation to risk of cancer and strong associations 
were claimed. Impact of diabetes on cancer inci-
dence and mortality was detected in meta-analyses 
and observational studies.1,2 Current researches 
show  that especially pancreatic, liver, endometri-
al, colorectal, bladder and breast cancer incidences 
are increased by the presence of diabetes.3,4 
Multiple and complex mechanisms were postu-
lated for the association between diabetes and can-
cer. These associations could be causal or because 
of common risk factors since type 2 diabetes and 
cancer are common chronic disorders. Cancer is 
the second and T2DM is the tenth leading cause of 
mortality in the latest global, regional and country-
level cause-specific mortality estimates for the year 
2015.5 There are also several shared confounding 
risk factors like age, sex, smoking, obesity, genet-
ics, diet and sedentary lifestyle.6 Interrelation be-
tween these factors usually can not be assessed.  
Possible Links Between Type 2 Diabetes 
Mellitus and Cancer
Hyperinsulinemia  
Hallmark of type 2 diabetes mellitus is desensitiza-
tion of target tissues to the actions of insulin which 
is called insulin resistance. This leads to compen-
satory increase in insulin production causing hy-
perinsulinemia. Insulin is known for its mitogenic 
properties.7 In previous studies, hyperinsulinemia 
was found to be linked with the occurance of the 
breast, colon, liver, esophagus, pancreas and endo-
metrium cancers.8 
The known metabolic and mitogenic effects of 
insulin are mediated by insulin receptors (InsR). 
There are two isoforms of InsR: InsRA and InsRB. 
InsRB regulates metabolic effects of insulin in pe-
ripheral target tissues. InsRA binds insulin, insulin-
like growth factor II (IGF-II) and proinsulin thus 
involved in mitogenic activities.7 InsRA is found 
to be overexpressed in cancers of breast, lung, thy-
roid, endometrium and ovaries.9 
IGF-1 was found to be increased in response to he-
patic stimulation of insulin.10 Insulin also increases 
IGF-1 via decreasing the production of IGF bind-
ing protein and inhibiting IGF-1 binding to other 
binding proteins.10 IGF-1 receptor is activated by 
insulin, IGF-1 and IGF-II, which is also involved in 
mitogenic signaling and tumor development. IGF-
1 stimulates MAPK/ERK and PI3K/Akt/mTOR 
(Phosphatidylinositol-3 kinases/Akt/ mammalian 
target of rapamycin) signaling pathways and inhib-
its PTEN (Phosphatase and tensin homolog deleted 
on chromosome 10) which leads to antiapoptotik 
activity.10 Some neoplastic cells generate hybrid 
insulin/IGF-1 receptors activated by insulin, IGF-1 
and IGF-2. In addition, chronic hyperinsulinemia 
leads to excessive growth of and progression to 
cancer by increasing glucose utilization. Nowa-
days, it is widely accepted that malignant trans-
formation generally involves hyperactivation of 
insulin, mTOR signaling pathway and genetical 
aberrations in metabolic signaling pathways.10 
Adipocytokines 
Adipose tissue is an important endocrine organ 
which releases adipokines and sex hormones.  In 
addition to direct effect of insulin, other pathways 
involved in central adiposity also induce malignant 
progression. The cytokines derived from adipose 
cells like tumor necrosis factor (TNF)-alpha, resis-
tin and interleukin IL-6 cause chronic inflammation 
and insulin resistance leading to malignant trans-
formation (11). In addition, adipose tissue releases 
VEGF (Vascular Endothelial Growth Factor) and 
MMPs (Matrix Metalloproteinases) which are in-
volved in tumor angiogenesis and metastasis.11 
The expression of adipocytokines are dysregulated 
in obesity. Leptin has pro-inflammatory effects 
and increases insulin resistance by ObR and LRb 
receptors. Signaling pathways activated (PI3K, 
MAPK and STAT) cause angiogenesis, mitogen-
esis and suppression of apoptosis.11
Another adipokine secreted from adipocytes called 
adiponectin, on the other hand, inhibits cell prolif-
eration and induces apoptosis.11 It activates AMPK 
signaling pathway which leads to inhibition of 
PI3K/AKT/mTOR signaling.
Insulin was reported to cause increased androgen 
production from the ovaries and adrenal gland.11 
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Besides that adipocytes secrete aromatase enzyme 
that cause conversion of androgens to estradiol. In-
sulin also decreases sex hormone binding globulin 
(SHBG) which results in high levels of circulating 
estradiol. It was hypothesized that this high estra-
diol levels caused by hyperinsulinism may lead to 
hormone sensitive cancers, like breast or endome-
trium cancers.11
Hyperglycemia
Hyperglycemia itself was also proposed to induce 
carcinogenesis by causing oxidative stres through 
DNA damage.12 The cancer and normal cells main-
ly differ according to their glucose consumption 
levels. The mutations that induce cancer some-
times affect glucose uptake pathways and result in 
a shift from mitochondrial oxidative phosphoryla-
tion to aerobic glycolysis, which is named Warburg 
effect.12 In that case,  cancer cells produce lactate 
from glucose even under hypoxic and low nutrient 
conditions as the major energy producing mecha-
nism. The oncogenic mutations in HIF-1 (Hypoxia 
inducible factor-1) and PI3K/Akt/mTOR phospho-
inositide 3-kinase/protein kinase B/mammalian 
target of rapamycin (PI3K/Akt/mTOR) pathways 
affect glucose uptake system through Warburg ef-
fect causing abnormal growth.12
Insulin Treatment and CancerRisk
It is assumed that insulin treatment may increase 
the risk of cancer by stimulatig related receptors. 
Several observational reports in 2009 claimed that 
a long acting insulin analogue, glargine, may cause 
increased  risk of cancer, specifically breast can-
cer.13,14 A conclusion was made as method and time 
related biases may have caused this apparently in-
creased cancer risk. ORIGIN trial assigning 12.537 
patients to standard care versus insulin glargine 
concluded that there was no risk increment for spe-
cific cancer types between the groups.15 
METFORMIN AND CANCER
Metformin is presently the first line recommended 
medication in T2DM.16 It is now found to have 
anti-cancerous effects mainly by targeting cancer 
signaling pathways.
In 2005, it was firstly reported that cancer inci-
dence was lower with metformin usage in patients 
with type 2 diabetes than those taking other anti-
diabetic medications.17 They found 23% decrease 
in risk of cancer in their retrospective study. Since 
then, multiple studies showed the association be-
tween metformin and the reduction of risk in can-
cers of pancreas, colorectal, stomach, liver, breast 
and esophagus in diabetes cases.18 Metformin was 
also claimed to improve survival in some cancers 
such as breast, pancreas, ovarian, colorectal, en-
dometrial, esophagus and prostate cancers.19 In 
a study published in 2013, metformin was found 
to increase 5-year survival in breast cancer and 
T2DM patients.20 Metformin was shown to reduce 
cancer risk of  31% and cancer mortality of 34% in 
a recent meta-analysis.21 
In an another recent meta-analysis which included 
265 studies, metformin or glitazones were linked 
with lower incidence of cancer but; oral antidia-
betic medications called sulfonylureas, insulin 
and alpha-glucosidase inhibitors were linked with 
increased incidence of cancer (RR= 0.86, 0.93 vs 
1.20, 1.21, 1.10 respectively).22  
Metformin was approved in Europe in 1958 and 
in USA in 1995 for use in type 2 diabetes melli-
tus which is an insulin sensitizer and mainly acts 
through inhibiting hepatic gluconeogenesis by ac-
tivating  LKB1 (liver kinase B1)/AMP-activated 
protein kinase (AMPK).23 It also stimulates periph-
eral glucose uptake by target tissues. This reduc-
tion in hepatic gluconeogenesis causes a reduction 
in hyperinsulinemia. This effect is supposed to de-
crease stimulation of IR-A, ultimately inhibiting 
cancer cell growth.24 Metformin was also found to 
inhibit IGF-1R and IR gene expressions demon-
strated in endometrial cancer cell lines and breast 
cancer patients.25 
Proofs for the Anti-cancerous Activity of 
Metformin
In diabetic patients who use metformin, pancreas 
cancer risk was found to be decreased significantly 
in female patients in comparison to patients who 
didn’t use metformin.26
Metformin use -after pancreatic cancer opera-
tion- resulted in a median survival of 35.5 months 
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in comparison to 20.2 months in non-users (HR 
0.668, 95% CI 0.397-1.125).27 
In colorectal carcinoma, metformin caused 44% 
reduction in all-cause mortality and 34% in risk of 
mortality.28 In colon cancer cells, metformin was 
demonstrated to increase apoptosis in p53 deficient 
cells.29
In postmenopausal women with diabetes, metform-
in was found to have  protective effect on breast 
cancer risk (OR 0.83, 95% CI 0.71-0.97).30 Strong-
er associations were found when analyses were 
limited to studies estimating the impact of longer 
metformin use (OR = 0.75. 95 % CI 0.62, 0.91). In 
early stage breast carcinoma, diabetic patients who 
were on metformin and neoadjuvant chemotherapy 
had beter pathological response compared to dia-
betics who did not use metformin (24% vs 8%).31 
Metformin was found to cause 44% reduction in 
prostate cancer risk in caucasian diabetic men.32
In diabetic women, metformin was suggested to 
decrease ovarian cancer incidence.33 It was also no-
ticed that metformin enhanced the anti-neoplastic 
effect of cisplatin in epithelial ovarian cancer cell 
lines.34
Some previous studies suggested that metformin 
causes a decreased incidence of lung cancer and 
increased the remission period.35,36 In mice with 
lung cancer, metformin inhibited the AKT and 
mTOR pathways resulting in 72% reduction in tu-
mor load.37
Preclinical studies show that metformin inhibits 
endometrial, ovarian and glioma cells.34,38,39 Met-
formin also causes decreased hepatocellular cancer 
incidence in diabetic patients.40 In hepatocellular 
cancer cells, metformin was found to decrease 
mitochondrial oxygen consumption and suppress 
hypoxia induced HIF-1 alpha accumulation which 
was shown to be involved in the development of 
hepatocellular cancer.41
In the non-diabetic cancer patients, metformin also 
shows good promises. In colorectal cancer, met-
formin addition to chemotherapy resulted in dis-
ease stabilization.42 Metformin reduces colorectal 
cancer risk probably through its local effect after 
oral intake in addition to its apoptotic effect in p53 
deficient cells.  
In a non-diabetic patient group of 102 women with 
breast cancer, metformin treated group (1700 mg/
day) in addition to 6 months of hormonal treatment, 
had significantly less metastasis.43 Metformin also 
caused significant reduction of IGF-1, insulin, and 
HOMA-IR and significant increase of IGFBP-3 
which is known as apoptosis inducer.43
Table 1 summarizes in vivo and in vitro studies that 
prove anticancerous effects of metformin in differ-
ent types of cancer.
Possible Mechanisms of Anti-cancerous Activity 
of Metformin
Metformin exhibits its anticancerous effects by 
inhibiting insulin resistance and some growth fac-
tors like mTOR (mammalian target of rapamycin), 
FASN and SREBP-1 through AMPK-dependent 
and independent systemic pathways.23 AMPK is a 
serine threonine protein kinase that inhibits protein 
synthesis and mTOR which is involved in cellular 
growth.44 Metformin activates AMPK by inhibiting 
complex 1 of mitochondrial respiratory chain, sug-
gesting that metformin’s effects are linked to the 
interference of energy signaling (causing an energy 
deficient state) and cellular metabolism (reduction 
of protein transit through nuclear pore complex 
causing decreased protein synthesis).45 Metformin 
also inhibits cyclin dependent kinases, down regu-
lates cyclin D1 levels and up-regulates p53 to p21 
axis.46 LKB1 is a tumor supressor gene which also 
activates AMPK. Metformin has cytotoxic and cy-
tostatic effects on cancer cells in LKB1/AMPK-de-
pendent or/and independent ways.45 AMPK-inde-
pendent effects of metformin are mediated through 
a negative regulator of mTOR called REDD1 
(regulated in development and DNA damage) by 
affecting cell cycle arrest and reduction in cyclin 
D1.47  
The appropriate dosage needed to activate AMPK 
is still not known.48 Many in vivo preclinical stud-
ies were shown to use extremely higher doses of 
metformin than antidiabetic doses.24 On the other 
hand, in an in vitro study by Sinnett-Smith J. et 
al, mTORC1 activity inhibition by metformin was 
found to be dose dependent and very low plasma 
concentrations (0.05 mM) of metformin was effec-
tive.49 In their study, they demonstrated that met-
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formin induced mTORC1 inhibition is greater in 
physiological glucose concentrations than supra-
physiological glucose levels in vitro. This means 
hyperglycemic states may mask the effect of met-
formin. This condition is in line with metformin’s 
ability to suppress mitochondrial respiration caus-
ing an energy crisis in the cancer cells.
Emerging studies report that metformin also sup-
presses IGF signaling pathway which may be an 
another anti-cancerous effect of the medication. 
The mechanism here could be indirectly by inhibit-
ing insulin, insulin binding proteins thus inhibiting 
hyperinsulinism and by decreasing IGF-1 induced 
avtivation of AKt/mTOR and G protein coupled re-
ceptor signaling.50   
Metformin was also reported to activate MAPK 
signalling pathway (JNK) resulting in apoptosis 
mediated effect and cell cycle arrest.51
Table 1. Proofs for the anti-cancerous activity of metformin performed in diabetic, non-diabetic patients and in vitro cell lines with 
different types of cancer
Cancer type/model Result T2DM References
Any 23% ↓ in risk of cancer + 17
Any 31% ↓ in risk of cancer 34% ↓ in cancer mortality + 21
Any ↓ in risk of cancer:  RR = 0.86, 95% CI 0.83-0.90, I2 = 88.61% + 22
Pancreas ↓ in risk in women, adj. OR: 0.43, 95% CI: 0.23-0.80 + 26
After pancreatectomy ↑survival of 35.5 m vs 20.2 m, HR 0.668, 95% CI 0.397-1.125 + 27
Colorectal 34% ↓ in risk of mortality + 28 
 Disease stabilization – 42
Colon cancer cells  ↑ apoptosis – 29
Breast ↑ 5-year survival + 20
	 ↓ breast cancer risk in postmenopausal women + 30
      (OR = 0.75. 95 % CI 0.62, 0.91)
	 ↑ pathological response when added to neoadjuvant chemotherapy  + 31
       (24 % vs 8 %)
	 ↓ numbers of metastatic cases, ↓ IGF-1, ↑IGFBP-3 – 43
Prostate 44 % ↓ in risk of prostate cancer + 32
Ovarian ↓	ovarian cancer risk (OR 0.61, CI 0.30-1.35),  + 33
 ↑ survival (5 yr) to 63% vs  23%
Ovarian cancer cell lines  Dose- time-dependent growth inhibition of OVCAR-3,  – 34
 OVCAR-4 cell lines and potentiated effect of cisplatin 
Lung ↑	overall survival in NSCLC: 20.0 months vs 13.1 months + 35
	 ↓ lung cancer risk of 39%-45% + 36
Glioma (stem like glioma  ↓self-renewal capacity, induces differentiation,  – 38
   initiating cells) ↓tumor-initiating potential of stem-like glioma-initiating cells
Endometrial cancer cell lines ↓cell proliferation in a dose-dependent manner – 39
Liver ↓ cancer risk, OR: 0.30, CI: 0.17, 0.52 + 40
HCC cell line ↓ hypoxia-induced HIF-1α protein content by promoting 
 protein degradation, ↓ mitochondrial oxygen consumption – 41
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In human breast cancer cells, metformin was found 
to suppress overexpressed HER2 (human epider-
mal growth factor receptor 2) pathway by AMPK 
independent way.52
Metformin was suggested to have anti-inflammato-
ry effects by decreasing activation of inflammatory 
factor NF-κB (nuclear factor kapa B) which is a 
transcription factor regulating proliferation and cell 
death.53 Possibly this anti-inflammatory effect also 
contributes to metformin’s anti-cancerous effect 
by growth inhibition and interfering the process 
of cellular transformation. Metformin -at doses of 
0.1 or 0.3 mM in vitro- was shown to inhibit NF-
κB, STAT3 transcription factor (signal transducer 
and activator of transcription 3), Let-7 microRNA 
family members, IL-6 and VEGF until 6 hours, the 
effect that is supposed to block transformation to 
cancer cell.53  
Cancer stem cells (CSCs) are cancer initiating cells 
which have potential to become a tumor. They 
were found to be both chemo- and radio-resist-
ant.54  In 2009, Hirsch et al. firstly reported that 
metformin selectively targeted cancer stem cells, 
directly blocking tumor growth and prolonging re-
mission.55 Cancer stem cells are also hypothesized 
to be involved in resistant metastatic disease.45 
Cancer stem cells are modulated mainly by mito-
chondria and metformin’s effect of mitochondrial 
intervention seems also to cause cancer stem cell 
inhibition.45,55 Another mechanism detected is inhi-
bition of Warburg effect by metformin and thus the 
growth of CSCs.56
Epithelial to mesenchymal transition has a very 
important role in metastasis formation. Metformin 
was demonstrated to inhibit this transition through 
blockage of mTOR signaling.57
Metformin may also have immuno-modulatory ef-
fects shown in animal studies. It was reported to 
inhibit apoptosis of CD8+ tumor infiltrating lym-
phocytes and CD8+ tumor induced lymphocytes 
and increases CD8+ memory T cells.58,59 
Some studies suggested that metformin may sensi-
tize cancer cells to some chemotherapy agents, in-
cluding cisplatin, doxorubicin and paclitaxel.34,55,60 
Metformin was also found to increase radiosensi-
tivity of cancer cells  through ATM and AMPK.61
Metformin was found to cause changes in the com-
position of intestinal microbiota. Increasing num-
ber of studies show that intestinal microbiota has a 
crucial role in the maintanance of immune system. 
Previous reports provide a link between alterations 
of the microbiota in the gastrointestinal system and 
obesity, type 2 diabetes mellitus, metabolic syn-
drome, cancer and aging.62 Metformin increases 
the abundance of Akkermansia, a mucus-degrading 
gram-negative bacteria in the gut, which is associ-
ated with restoration of reduced regulatory T cells 
and amelioration of low-grade tissue inflammation 
in the adipose tissue of obese animals.63 This ef-
fect of metformin on intestines probably causes 
anti-aging and anti-cancerous effects and  life span 
extension, the effects which need verification.64 
The North American Breast Cancer Group is exe-
cuting a placebo-controlled and randomised phase 
III trial in 3649 non-diabetic women with early 
stage breast cancer to see the utility of metformin 
in breast cancer which was planned for 5 years.65 
Early results show reduction in insulin resistance 
(-17.1%) and inflammatory markers. There are 3 
clinical studies currently evaluating survival ben-
efit of metformin in breast cancer but the results are 
not obtained yet.59 The long-term results of these 
studies may clear up the utility of metformin in 
cancer treatment.  
Clinical trials showed low incidence of side effects 
and dose limiting toxicity with metformin espe-
cially in the cases of combinations with chemo-
therapy agents.66
The overall final effects of metformin in cancer 
seem to increase apoptosis, cell cycle arrest and to 
inhibit protein synthesis, cell proliferation, metas-
tasis and invasion.67 Possible mechanisms causing 
anti-cancerous effects of metformin are summa-
rized in Figure 1.
In conclusion, wide range of studies indicate that 
metformin looks like a promising candidate in can-
cer prevention and treatment. It was also claimed 
to improve survival in some cancers. Metformin 
has anti-cancerous and anti-metastatic effects 
mainly through activating AMPK dependent and 
independent signaling; inhibiting mTOR, MAPK, 
HER2, NF-κB, IGF signaling pathways and with 
its possible immuno-modulatory effects. Further 
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studies are needed to evaluate the potential of met-
formin as adjuvant therapy for cancer especially in 
non-diabetic patients.
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